Yesterday in part 1 (Link) of our latest mini-series, we looked at the SCLC landscape and some of the key background issues to think about.
This time around in part 2 we drill down focus more specifically on Rova-T, including physician and patient sentiments and in particular, what to watch out for with the upcoming phase 2 TRINITY readout. There’s a lot to consider here so we’ve broken the analysis down to five key areas.
Mystic Meg is also back with her canny predictions – what does the crystal ball portend for Rova-T and the TRINITY trial? Caveat: she’s been on a tear of late; this situation will not continue forever.